STUDY TITLE: - Early Metabolic Changes with Thiazide or Beta blocker Therapy for Essential Hypertension – open label extension phase with the potassium sparing diuretic- Amiloride.
- Conditions
- Essential hypertension
- Registration Number
- EUCTR2007-005655-42-GB
- Lead Sponsor
- Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Our ongoing, previously approved study is a double-blind, placebo controlled, cross-over study, of approximately 66 patients in which each patient receives in random order, 4 weeks treatment with either Bendrofluazide 5-10mg daily, Atenolol 50-100mg daily or combination of Bendrofluazide 2.5-5.0mg and Atenolol 25-50mg daily.
Patients who have completed the main part of the study will be invited to take part in an open label phase with 10mg of amiloride for 2 weeks increasing to 20mg amiloride for 2 weeks.
Are the trial subjects under 18?
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
All patients will have taken part in the previous study and the original exclusion criteria still therefore stand:
Any patient already taking thiazide diuretics or beta blockers in whom these drugs cannot be switched to alternative drugs with similar or better blood pressure control.
Any patient who is intolerant of these medications will be excluded from the study.
Patients with gout, asthma or any other contraindications to the study drugs will be excluded.
Women of child bearing age not using contraception.
Volunteers with heart failure, liver failure, renal failure, terminal illnesses (e.g. cancer)
Volunteers not able to give informed consent
Patients with diabetes
New exclusion criteria include:
Patients with plasma potassium over 5.5mmol/l, concomitant use of other potassium sparing agents or potassium supplements, anuria, acute renal failure, severe progressive renal disease (ie patients at highest risk of hyperkalaemia) would all be excluded from this study.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: Can the oral glucose tolerance test detect changes after 4 weeks treatment with the potassium sparing diuretic - amiloride hydrochloride?;Secondary Objective: Are metabolic changes different in patients treated with atenolol, bendroflumethiazide and amiloride?;Primary end point(s): Change in 2 hour glucose between amiloride treatment at 10mg vs 20mg vs baseline.
- Secondary Outcome Measures
Name Time Method